Atrium Therapeutics Stock (NASDAQ:RNA)

Forecast Revenue Ownership Financials Chart

Previous Close

$11.67

52W Range

$11.40 - $16.77

50D Avg

$13.11

200D Avg

$13.40

Market Cap

$212.62M

Avg Vol (3M)

$382.75K

Beta

0.42

Div Yield

-

RNA Company Profile

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

511

IPO Date

Feb 27, 2026

Website

RNA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Reportable Segment	$18.75M	$10.90M

Fiscal year ends in Dec 25 | Currency in USD

RNA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$18.75M	$10.90M	$9.56M
Operating Income	$-745.94M	$-378.94M	$-235.60M
Net Income	$-684.63M	$-322.30M	$-212.22M
EBITDA	$-745.94M	$-376.16M	$-233.50M
Basic EPS	$-4.97	$-2.89	$-2.91
Diluted EPS	$-4.97	$-2.89	$-2.91

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 14Nov 17, 14 | 5:00 PM

Q2 14Aug 12, 14 | 5:00 PM

Q1 14May 20, 14 | 5:00 PM